CD47-SIRPα相互作用作为“不要吃我”的信号,被癌症利用来下调先天和适应性免疫监测。人们对发展封锁机制有着浓厚的兴趣,我们的目标是分析早期临床试验的新数据。我们对相关数据库和会议摘要进行了系统评价和荟萃分析,包括在癌症治疗中使用CD47和/或SIRPα抑制剂的临床试验。非线性混合模型用于比较响应和毒性。我们检索了317篇文章,其中24人符合资格。其中包括771例血液系统(47.1%)和实体瘤(52.9%)的可评估反应的患者。其中,6.4%有完全反应,10.4%部分反应,和26.1%稳定的疾病,16.7%的客观反应率(ORR),疾病控制率42.8%,和4.8个月的中位缓解期。血液系统癌症的ORR(25.3%)明显高于实体癌(9.1%,p=0.042)。按机制比较,7种CD47单克隆抗体(mAb)和6种选择性SIRPα阻断剂单独给予或与检查点抑制剂联合给予,靶向治疗,和/或化疗。在实体癌症中,选择性SIRPα阻断显示出比抗CD47单克隆抗体(2.8%,p=0.079),这对于联合治疗是显著的(ORR28.3%vs3.0%,分别,p=0.010)。在头部和颈部看到了反应,结直肠,子宫内膜,卵巢,肝细胞,非小细胞肺,和HER2+胃食管癌。在3.3%的患者中观察到剂量限制性毒性(DLT)(5.4%的抗CD47单克隆抗体,1.4%选择性SIRPα受体阻滞剂;p=0.01)。治疗相关不良事件(TRAEs)≥3级的发生率为18.0%,两组相似(p=0.082),主要是实验室异常。对于抗CD47单克隆抗体,最常见的毒性包括1-2级疲劳(27.2%),头痛(21.0%),贫血(20.5%)。对于选择性SIRPα阻断剂,其中包括1-2级输注反应(23.1%)和疲劳(15.8%).抗CD47单克隆抗体比选择性SIRPα受体阻滞剂更有可能导致1-2级发热,发冷,恶心/呕吐,头痛,和贫血。总之,使用选择性SIRPα阻断的联合治疗在实体瘤中的应答率高于抗CD47mAb联合治疗.血液学改变是主要的TRAEs,选择性SIRPα受体阻滞剂似乎具有更好的1-2级毒性。治疗耐受性良好,DLT最少。
CD47-SIRPα interaction acts as a \"don\'t eat me\" signal and is exploited by cancer to downregulate innate and adaptive immune surveillance. There has been intense interest to develop a mechanism of blockade, and we aimed to analyze the emerging data from early clinical trials. We performed a systematic
review and meta-analysis of relevant databases and conference abstracts including clinical trials using CD47 and/or SIRPα inhibitors in cancer treatment. Nonlinear mixed models were applied for comparison of response and toxicity. We retrieved 317 articles, 24 of which were eligible. These included 771 response-evaluable patients with hematologic (47.1%) and solid tumors (52.9%). Of these, 6.4% experienced complete response, 10.4% partial response, and 26.1% stable disease for a 16.7% objective response rate (ORR), 42.8% disease control rate, and 4.8-month median duration of response. ORR was significantly higher for hematologic cancers (25.3%) than solid cancers (9.1%, p=0.042). Comparing by mechanism, seven CD47 monoclonal antibodies (mAbs) and six selective SIRPα blockers were given alone or combined with checkpoint inhibitors, targeted therapy, and/or chemotherapy. In solid cancers, selective SIRPα blockade showed a higher ORR (16.2%) than anti-CD47 mAbs (2.8%, p=0.079), which was significant for combination therapies (ORR 28.3% vs 3.0%, respectively, p=0.010). Responses were seen in head and neck, colorectal, endometrial, ovarian, hepatocellular, non-small cell lung, and HER2+gastroesophageal cancers. Dose-limiting toxicity (DLT) was seen in 3.3% of patients (5.4% anti-CD47 mAbs, 1.4% selective SIRPα blockers; p=0.01). The frequency of treatment-related adverse events (TRAEs) ≥grade 3 was 18.0%, similar between the two groups (p=0.082), and mostly laboratory abnormalities. For anti-CD47 mAbs, the most common toxicities included grade 1-2 fatigue (27.2%), headache (21.0%), and anemia (20.5%). For selective SIRPα blockers, these included grade 1-2 infusion reaction (23.1%) and fatigue (15.8%). Anti-CD47 mAbs were significantly more likely than selective SIRPα blockers to cause grade 1-2 fever, chills, nausea/vomiting, headache, and anemia. In conclusion, combination therapies using selective SIRPα blockade had higher response rates in solid tumors than anti-CD47 mAb combinations. Hematologic changes were the main TRAEs, and selective SIRPα blockers seemed to have a better grade 1-2 toxicity profile. Treatment was well-tolerated with minimal DLTs.